Chemotherapy of vulvar cancer

A review

Gunter Deppe, Ismail Mert, Jimmy Belotte, Ira S. Winer

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Squamous cell carcinoma of the vulva is a rare disease with good prognosis if diagnosed early. The standard primary therapy is surgery. Neoadjuvant radiation or chemotherapy has been used to achieve resectability of the tumor and to decrease the radicality of the surgery. Chemotherapy with platinum compounds, paclitaxel and targeted therapy (erlotinib) has shown activity. International collaborative trials are needed to identify the best therapeutic strategy for patients with squamous cell cancer of the vulva who are not candidates for primary surgery or concomitant chemoradiation. We review the various treatment options available to patients with advanced or recurrent squamous cell cancer of the vulva.

Original languageEnglish (US)
Pages (from-to)119-128
Number of pages10
JournalWiener Klinische Wochenschrift
Volume125
Issue number5-6
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Vulvar Neoplasms
Drug Therapy
Squamous Cell Neoplasms
Platinum Compounds
Vulva
Therapeutics
Rare Diseases
Paclitaxel
Squamous Cell Carcinoma
Radiation
Neoplasms

Keywords

  • Chemotherapy
  • Vulvar cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chemotherapy of vulvar cancer : A review. / Deppe, Gunter; Mert, Ismail; Belotte, Jimmy; Winer, Ira S.

In: Wiener Klinische Wochenschrift, Vol. 125, No. 5-6, 01.03.2013, p. 119-128.

Research output: Contribution to journalReview article

Deppe, Gunter ; Mert, Ismail ; Belotte, Jimmy ; Winer, Ira S. / Chemotherapy of vulvar cancer : A review. In: Wiener Klinische Wochenschrift. 2013 ; Vol. 125, No. 5-6. pp. 119-128.
@article{ad985c767bc546b6958a30b26c704008,
title = "Chemotherapy of vulvar cancer: A review",
abstract = "Squamous cell carcinoma of the vulva is a rare disease with good prognosis if diagnosed early. The standard primary therapy is surgery. Neoadjuvant radiation or chemotherapy has been used to achieve resectability of the tumor and to decrease the radicality of the surgery. Chemotherapy with platinum compounds, paclitaxel and targeted therapy (erlotinib) has shown activity. International collaborative trials are needed to identify the best therapeutic strategy for patients with squamous cell cancer of the vulva who are not candidates for primary surgery or concomitant chemoradiation. We review the various treatment options available to patients with advanced or recurrent squamous cell cancer of the vulva.",
keywords = "Chemotherapy, Vulvar cancer",
author = "Gunter Deppe and Ismail Mert and Jimmy Belotte and Winer, {Ira S.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/s00508-013-0338-y",
language = "English (US)",
volume = "125",
pages = "119--128",
journal = "Wiener Klinische Wochenschrift",
issn = "0043-5325",
publisher = "Springer Wien",
number = "5-6",

}

TY - JOUR

T1 - Chemotherapy of vulvar cancer

T2 - A review

AU - Deppe, Gunter

AU - Mert, Ismail

AU - Belotte, Jimmy

AU - Winer, Ira S.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Squamous cell carcinoma of the vulva is a rare disease with good prognosis if diagnosed early. The standard primary therapy is surgery. Neoadjuvant radiation or chemotherapy has been used to achieve resectability of the tumor and to decrease the radicality of the surgery. Chemotherapy with platinum compounds, paclitaxel and targeted therapy (erlotinib) has shown activity. International collaborative trials are needed to identify the best therapeutic strategy for patients with squamous cell cancer of the vulva who are not candidates for primary surgery or concomitant chemoradiation. We review the various treatment options available to patients with advanced or recurrent squamous cell cancer of the vulva.

AB - Squamous cell carcinoma of the vulva is a rare disease with good prognosis if diagnosed early. The standard primary therapy is surgery. Neoadjuvant radiation or chemotherapy has been used to achieve resectability of the tumor and to decrease the radicality of the surgery. Chemotherapy with platinum compounds, paclitaxel and targeted therapy (erlotinib) has shown activity. International collaborative trials are needed to identify the best therapeutic strategy for patients with squamous cell cancer of the vulva who are not candidates for primary surgery or concomitant chemoradiation. We review the various treatment options available to patients with advanced or recurrent squamous cell cancer of the vulva.

KW - Chemotherapy

KW - Vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=84884808910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884808910&partnerID=8YFLogxK

U2 - 10.1007/s00508-013-0338-y

DO - 10.1007/s00508-013-0338-y

M3 - Review article

VL - 125

SP - 119

EP - 128

JO - Wiener Klinische Wochenschrift

JF - Wiener Klinische Wochenschrift

SN - 0043-5325

IS - 5-6

ER -